Musaffa Logo
ACADIA Pharmaceuticals Inc DR6.SG

Last Updated: Jul 16, 12:00 AM·XSTU

DR6.SG Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, ACADIA Pharmaceuticals Inc is classified as halal.

HALAL

Report Source: 2026 1st Quarter Report

ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc. Stock Analysis DR6.SG

Germany Health Care Mid Cap Report:
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 796 full-time employees. The company went IPO on 2004-05-27. The firm is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. The company is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Read More

ACADIA Pharmaceuticals Inc (DR6.SG) Chart

Key Statistics of ACADIA Pharmaceuticals Inc (DR6.SG)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€22.29€22.80

Today's Open

€22.41

Volume

-

P/E Ratio (TTM)

11.29

Financial Metrics & Statements of ACADIA Pharmaceuticals Inc (DR6.SG)

Super Investors Invested in ACADIA Pharmaceuticals Inc (DR6.SG)

FAQ's for ACADIA Pharmaceuticals Inc (DR6.SG)

  • As of July 2026, ACADIA Pharmaceuticals Inc DR6.SG is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ACADIA Pharmaceuticals Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in ACADIA Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of ACADIA Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of ACADIA Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of ACADIA Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.